Background
==========

The increasing frequency of methicillin-resistant Staphylococcus aureus as a cause of surgical site infections, and decreased susceptibility to vancomycin, highlight the need for alternative therapies. Daptomycin is a novel lipopeptide antibiotic used in the treatment of certain infections caused by Gram-positive organisms. It is a naturally-occurring compound found in the soil saprotroph Streptomyces roseosporus. Its distinct mechanism of action means that it may be useful in treating infections caused by multi-resistant bacteria Daptomycin is approved for the treatment of skin and skin-structure infections (4 mg/kg), and Staphylococcus aureus bacteremia, including right-sided endocarditis (6 mg/kg).

Aim
===

To evaluate the safety and efficacy of daptomycin when administered for a variety of gram-positive infections in a single neurosurgical unit.

Materials and methods
=====================

During the last three years we use damtomycin (2006-2007-2008) in 64 cases. For the purpose of this study, the safety and efficacy of daptomycin were evaluated in patients who received doses of 4 mg/kg or higher. Prior antibiotic therapy was given to 21,8% of patients (14).

Results
=======

The median final daptomycin dose was 5 mg/kg. The median duration of daptomycin therapy was 15 days. Daptomycin was well tolerated in patients with gram-positive infections.The most common infections were skin and skin-structure. The most common pathogens were S. aureus.

1\. A large number of novel antibacterial agents have been or are being developed for the treatment of complicated skin and soft tissue infections -cSSTIs -Daptomycin is one of them and it is available for clinical use. 2.Daptomycin was well tolerated in patients with gram-positive infections. 3. Further prospective and comparative studies of daptomycin are warranted.

Conclusions
===========

We have always to rememder that the most mportant parameters that appear to determine the clinical effectiveness of an antibiotic for cSSTIs include the severity of the illness, patient co-morbidities, whether the patient receives appropriate antimicrobial therapy at the onset of illness and if this should be a combination or single-agent approach to cover a broad range of likely causative organisms.
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